1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,021 | 0,023 | 16:14 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.09. | Genflow Biosciences reports positive anti-ageing dog trial results | 1 | Alliance News | ||
| 08.09. | Genflow: Gentherapie-Studie an Hunden erreicht primären Endpunkt | 2 | Investing.com Deutsch | ||
| 08.09. | Genflow meets primary endpoint in aged dog gene therapy trial | 2 | Investing.com | ||
| 08.09. | Genflow Biosciences PLC Announces Primary Endpoint in SLAB Clinical Trial Met | 217 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 08.09. | Genflow Biosciences - Primary Endpoint in SLAB Clinical Trial Met | 1 | RNS | ||
| GENFLOW BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 07.09. | Genflow Biosciences PLC Announces Appointment of Investor Relations Adviser | 226 | ACCESS Newswire | LONDON, UK / ACCESS Newswire / September 7, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), an emerging leader in the field of longevity research, today announces... ► Artikel lesen | |
| 07.09. | Genflow Biosciences - Appointment of Investor Relations Adviser | - | RNS | ||
| 03.08. | Genflow Biosciences PLC Announces Patent Update | 283 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 03.08. | Genflow Biosciences - Patent Update | 1 | RNS | ||
| 13.07. | Genflow meldet positive Studiendaten bei Hunden und sichert sich LNP-Partnerschaft | 1 | Investing.com Deutsch | ||
| 13.07. | Genflow reports positive dog trial data, secures LNP partnership | 1 | Investing.com | ||
| 13.07. | Genflow Biosciences PLC Announces Mid-Year Operational and Corporate Summary | 430 | ACCESS Newswire | LONDON, UK / ACCESS Newswire / July 13, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or the "Company"), an emerging leader in the field of longevity research, provides a mid-year... ► Artikel lesen | |
| 13.07. | Genflow Biosciences - Mid-Year Operational and Corporate Summary | - | RNS | ||
| 29.06. | Genflow Biosciences PLC Announces Result of AGM | 304 | ACCESS Newswire | LONDON, UK / ACCESS Newswire / June 29, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, is pleased to announce... ► Artikel lesen | |
| 29.06. | Genflow Biosciences - Result of AGM | 1 | RNS | ||
| 22.06. | Genflow Biosciences PLC Announces Participation at BIO International Convention 2026 | 289 | ACCESS Newswire | LONDON, UK / ACCESS Newswire / June 22, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, today announces Gad... ► Artikel lesen | |
| 22.06. | Genflow Biosciences - Participation at BIO International Convention 2026 | - | RNS | ||
| 17.06. | Genflow präsentiert im Oktober Daten zur Gentherapie bei alternden Hunden | 2 | Investing.com Deutsch | ||
| 17.06. | Genflow to present aged dog gene therapy data in October | 4 | Investing.com | ||
| 17.06. | Genflow Biosciences PLC - Company to present at Animal Longevity Summit 2026 | 266 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen |
1 2 3 Weiter >>
58 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CRISPR THERAPEUTICS | 51,73 | +0,37 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results | ZUG, Switzerland and BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the second quarter ended June 30, 2026. "The second quarter reflected... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,248 | -3,14 % | PacBio Appoints Mark Van Oene as President and Chief Executive Officer | MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) ("PacBio"), a leading developer of high-quality, highly accurate sequencing solutions,... ► Artikel lesen | |
| DENALI THERAPEUTICS | 18,765 | -0,58 % | Mehr als 98% bleiben draußen: Warum Roche, Denali und NurExone neue Wege ins Nervensystem suchen | ||
| VOYAGER THERAPEUTICS | 2,690 | 0,00 % | Voyager Therapeutics, Inc.: Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer's Disease Expected H2 2026 | - Data presented as Developing Topics poster at AAIC 2026 - LEXINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging... ► Artikel lesen | |
| BIOAGE LABS | 7,515 | +1,76 % | BioAge Labs: Fokus auf Wirkstoff BGE-102 trotz strategischer Neuausrichtung | ||
| LINEAGE CELL THERAPEUTICS | 0,917 | +0,44 % | Transcript: Lineage Cell Therapeutics Q1 2026 Earnings Conference Call | ||
| BIOPHYTIS | 0,048 | 0,00 % | XFRA 6XB3: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| SERINA THERAPEUTICS | 2,000 | -2,91 % | Serina Therapeutics, Inc.: Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson's Disease and Advances to Cohort 2 | - Independent Safety Monitoring Committee recommends advancement to Cohort 2 following blinded review of Cohort 1 safety and tolerability data - - Pharmacokinetic observations at the lowest dose... ► Artikel lesen | |
| LONGEVERON | 2,675 | -1,65 % | Morning Market Movers: Aethlon Medical, CID HoldCo, Longeveron, Delixy See Big Swings | OTTAWA (dpa-AFX) - At 8:50 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| MODERNA | 165,82 | +4,03 % | Moderna-Aktie mit +35% - steht der Ausbruch bevor? | Die Moderna-Aktie hat gestern +12,27% zugelegt und notiert inzwischen bei 172,94 US$. Damit erreicht der Kurs eine entscheidende Widerstandszone. Während RSI und MACD eine starke Aufwärtsdynamik bestätigen... ► Artikel lesen | |
| QIAGEN | 38,290 | -0,31 % | Heidelberg Materials schwächelt weiter, Qiagen zieht an: DAX-Ausblick | Der DAX bleibt im Konsolidierungsmodus. Nach einer zwischenzeitlichen Erholung geriet das größte deutsche Börsenbarometer am Freitag wieder unter Abgabedruck. Auf Wochensicht summierten sich die Abschläge... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 16,950 | -0,99 % | Cantor Fitzgerald reiterates Overweight on Summit Therapeutics stock | ||
| PRAXIS PRECISION MEDICINES | 297,08 | -1,19 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| IMMUNOVANT | 35,730 | -4,18 % | Immunovant ends cutaneous lupus program after phase 2 flop | ||
| KYMERA THERAPEUTICS | 120,42 | -1,30 % | Stifel raises Kymera Therapeutics price target on drug trial outlook |
GENFLOW BIOSCIENCES PLC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,021 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENFLOW BIOSCIENCES PLC finden Sie auf Wallstreet Online.